SAMEH, Attia, Mausbach KATHARINA, Miloslav KLUGAR, Howaldt HANS-PETER and Abanoub RIAD. Prevalence and Drivers of COVID-19 Vaccine Booster Hesitancy Among German University Students and Employees. Frontiers in Public Health. Lausanne: Frontiers, 2022, vol. 10, April 2022, p. 1-17. ISSN 2296-2565. Available from: https://dx.doi.org/10.3389/fpubh.2022.846861.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Prevalence and Drivers of COVID-19 Vaccine Booster Hesitancy Among German University Students and Employees
Authors SAMEH, Attia (guarantor), Mausbach KATHARINA, Miloslav KLUGAR (203 Czech Republic, belonging to the institution), Howaldt HANS-PETER and Abanoub RIAD (818 Egypt, belonging to the institution).
Edition Frontiers in Public Health, Lausanne, Frontiers, 2022, 2296-2565.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30304 Public and environmental health
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.200
RIV identification code RIV/00216224:14110/22:00125640
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3389/fpubh.2022.846861
UT WoS 000790329700001
Keywords in English cross-sectional studies; COVID-19 vaccines; decision making; Germany; social determinants of health; vaccination hesitancy
Tags 14110525, 14119612, 14119613, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 5/4/2023 08:15.
Abstract
COVID-19 booster hesitancy (VBH) is a serious public health challenge which acts simultaneously with the waning vaccine-elicited immunity and the emerging viral variants to prolong the pandemic interval. Therefore, this study aimed to evaluate the prevalence of COVID-19 VBH among a highly educated subset of the German population and to explore the potential demographic, anamnestic, and psychosocial determinants of this problem. A cross-sectional survey-based study was conducted in December 2021 among German university students and employees to evaluate their attitudes toward COVID-19 vaccine booster (VB) doses. The study used a self-administered questionnaire that was developed and disseminated digitally, and the questionnaire inquired about participants' demographic characteristics, COVID-19-related anamnesis, COVID-19 vaccine-related anamnesis, and psychosocial predictors of COVID-19 VBH. A total of 930 participants were recruited, of which 608 (65.4%) were students, 682 (73.3%) were females, and their mean age was 29.08 ± 10.93 years. Fifty-five participants (5.9%) had been previously infected by COVID-19 and the vast majority of infections happened before the first vaccine dose. Over 95% of the participants had received at least one vaccine dose, and the most commonly administered vaccine was BNT162b2. The overall COVID-19 VB acceptance was satisfactory (87.8%) and induced by various altruistic promoters, e.g., family health protection, community health protection, and patients' health protection. The students (86.3%), the previously infected participants (76.4%), the participants who did not receive primer doses of COVID-19 vaccines (2.5 %), and those who were hospitalized (40%) and sought medical care/treatment after receiving primer doses (86.8%) were less likely to accept COVID-19 VB compared to the employees (90.7%), the participants who were not previously infected (88.6%) and those who received primer dose (91.7%), and the participants who were not hospitalized (92%) nor sought medical care/treatment after primer doses (92.9%), respectively. The perceived effectiveness of COVID-19 VB against severe illness (adjusted odds ratio “AOR”: 47.65–95% confidence interval “CI”: 23.65–96.49), symptomatic infection (AOR: 9.87–95% CI: 5.20–18.71), community transmission (AOR: 5.34–95% CI: 3.00–9.49) and emerging variants (AOR: 19.12–95% CI: 10.57–34.55) were key predictors for COVID-19 VB acceptance; therefore, it needs to be highlighted in vaccine messaging. In addition, the perceived safety of COVID-19 VB and ethical dilemmas of vaccine justice need to be addressed publicly.
Links
EF19_073/0016943, research and development projectName: Interní grantová agentura Masarykovy univerzity
MUNI/A/1402/2021, interní kód MUName: Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu IV
Investor: Masaryk University
MUNI/IGA/1104/2021, interní kód MUName: COVID-19 Vaccines Safety Tracking in the Czech Republic (Acronym: CoVaST-CZ)
Investor: Masaryk University
PrintDisplayed: 18/7/2024 00:37